stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Free cash flow
Protagonist Therapeutics, Inc.'s free cash flow for fiscal 2025 was $56.1M, down 69.3% from $182.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was $130.6M. Over the past ten years it has ranged from −$109.0M (fiscal 2021) to $182.8M (fiscal 2024); the current reading is higher than 91% of that period. Protagonist Therapeutics, Inc. ranks 25th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $56.1M | (69.32%) |
| FY2024 | $182.8M | — |
| FY2023 | −$70.8M | — |
| FY2022 | −$108.9M | — |
| FY2021 | −$109.0M | — |
| FY2020 | −$73.0M | — |
| FY2019 | −$42.5M | — |
| FY2018 | −$50.4M | — |
| FY2017 | $3.2M | — |
| FY2016 | −$30.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $218.9M | — |
| Mar 2026 | −$49.2M | — |
| Dec 2025 | −$37.1M | — |
| Sep 2025 | −$2.0M | — |
| 41 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $310.1M |
| PTGX Protagonist Therapeutics, Inc. | $130.6M |
| CAI Caris Life Sciences,�Inc. compare | $83.9M |
| TGTX TG Therapeutics, Inc. compare | $17.4M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$168.7M |
| SYRE Spyre Therapeutics, Inc. compare | −$249.3M |
| IBRX ImmunityBio, Inc. compare | −$288.1M |
| CYTK Cytokinetics, Incorporated compare | −$588.6M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement